Matches in Wikidata for { <http://www.wikidata.org/entity/Q65393780> ?p ?o ?g. }
Showing items 1 to 34 of
34
with 100 items per page.
- Q65393780 description "clinical trial" @default.
- Q65393780 description "ensayu clínicu" @default.
- Q65393780 description "klinisch onderzoek" @default.
- Q65393780 description "клінічне випробування" @default.
- Q65393780 description "կլինիկական փորձարկում" @default.
- Q65393780 name "BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q65393780 name "BI 655066/ABBV-066" @default.
- Q65393780 type Item @default.
- Q65393780 label "BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q65393780 label "BI 655066/ABBV-066" @default.
- Q65393780 prefLabel "BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" @default.
- Q65393780 prefLabel "BI 655066/ABBV-066" @default.
- Q65393780 P1050 Q65393780-25B8FC8B-EA80-4B6A-B716-7077C789742C @default.
- Q65393780 P1132 Q65393780-471A9CF1-E9B6-4647-8A27-41A7D67B1E5C @default.
- Q65393780 P1476 Q65393780-CA70301D-2320-45BC-B24D-ACDD1E306312 @default.
- Q65393780 P2899 Q65393780-42DF59F6-21EB-4BFF-87DF-3EFACF27955D @default.
- Q65393780 P3098 Q65393780-8D3F8795-4D00-4C37-962D-3EDB2D426096 @default.
- Q65393780 P31 Q65393780-0ED1EB00-912A-4F6A-ABF9-E5AA9ACDC6FB @default.
- Q65393780 P580 Q65393780-EB042EAB-6E21-4FB4-9003-9F52932777AF @default.
- Q65393780 P582 Q65393780-C6CE6574-08D3-4BCC-BE61-DCDC6485602F @default.
- Q65393780 P6099 Q65393780-FC0F0E38-30C7-41BA-8C8C-8DEAC481EE66 @default.
- Q65393780 P8363 Q65393780-427093DF-5628-465D-AD49-B5270062ADAD @default.
- Q65393780 P921 Q65393780-155DC278-6426-40D4-A331-1DD075289D6B @default.
- Q65393780 P1050 Q179945 @default.
- Q65393780 P1132 "+684" @default.
- Q65393780 P1476 "BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)" @default.
- Q65393780 P2899 "+18" @default.
- Q65393780 P3098 "NCT02694523" @default.
- Q65393780 P31 Q30612 @default.
- Q65393780 P580 "2016-03-01T00:00:00Z" @default.
- Q65393780 P582 "2017-08-01T00:00:00Z" @default.
- Q65393780 P6099 Q42824827 @default.
- Q65393780 P8363 Q78089383 @default.
- Q65393780 P921 Q949302 @default.